TY - JOUR
T1 - Disease progression to bipolar disorder among adolescents and young adults with antidepressant-resistant and antidepressant-responsive depression
T2 - Does antidepressant class matter?
AU - Hsu, Ju Wei
AU - Chen, Li Chi
AU - Tsai, Shih Jen
AU - Huang, Kai Lin
AU - Bai, Ya Mei
AU - Su, Tung Ping
AU - Chen, Tzeng-Ji
AU - Chen, Mu Hong
N1 - Publisher Copyright:
© 2023 Elsevier B.V. and ECNP
PY - 2023/9
Y1 - 2023/9
N2 - Studies have demonstrated a positive relationship between antidepressant resistance and the progression of bipolar disorder. However, the influence of antidepressant classes such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) in this context has yet to be investigated. A total of 5,285 adolescents and young adults with antidepressant-resistant depression and 21,140 with antidepressant-responsive depression were recruited in the present study. The antidepressant-resistant depression group was divided into two subgroups: only resistant to SSRIs (n = 2,242, 42.4%) and additionally resistant to non-SSRIs (n = 3,043, 57.6%) groups. The status of bipolar disorder progression was monitored from the date of depression diagnosis to the end of 2011. Patients with antidepressant-resistant depression were more likely to develop bipolar disorder during the follow-up (hazard ratio [HR]: 2.88, 95% confidence interval [CI]: 2.67–3.09) than those with antidepressant-responsive depression. Furthermore, the group that was additionally resistant to non-SSRIs were at the highest risk of bipolar disorder (HR: 3.02, 95% CI: 2.76–3.29), followed by the group that was only resistant to SSRIs (2.70, 2.44–2.98). Adolescents and young adults with antidepressant-resistant depression, especially those who responded poorly to both SSRIs and SNRIs, were at increased risk of subsequent bipolar disorder compared with those with antidepressant-responsive depression. Further studies are warranted to elucidate the molecular pathomechanisms underlying the resistance to SSRIs and SNRIs and subsequent bipolar disorder.
AB - Studies have demonstrated a positive relationship between antidepressant resistance and the progression of bipolar disorder. However, the influence of antidepressant classes such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) in this context has yet to be investigated. A total of 5,285 adolescents and young adults with antidepressant-resistant depression and 21,140 with antidepressant-responsive depression were recruited in the present study. The antidepressant-resistant depression group was divided into two subgroups: only resistant to SSRIs (n = 2,242, 42.4%) and additionally resistant to non-SSRIs (n = 3,043, 57.6%) groups. The status of bipolar disorder progression was monitored from the date of depression diagnosis to the end of 2011. Patients with antidepressant-resistant depression were more likely to develop bipolar disorder during the follow-up (hazard ratio [HR]: 2.88, 95% confidence interval [CI]: 2.67–3.09) than those with antidepressant-responsive depression. Furthermore, the group that was additionally resistant to non-SSRIs were at the highest risk of bipolar disorder (HR: 3.02, 95% CI: 2.76–3.29), followed by the group that was only resistant to SSRIs (2.70, 2.44–2.98). Adolescents and young adults with antidepressant-resistant depression, especially those who responded poorly to both SSRIs and SNRIs, were at increased risk of subsequent bipolar disorder compared with those with antidepressant-responsive depression. Further studies are warranted to elucidate the molecular pathomechanisms underlying the resistance to SSRIs and SNRIs and subsequent bipolar disorder.
KW - Adolescents
KW - Antidepressant-resistant depression
KW - Antidepressant-responsive depression
KW - Bipolar disorder
KW - Young adults
UR - http://www.scopus.com/inward/record.url?scp=85160314352&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2023.04.018
DO - 10.1016/j.euroneuro.2023.04.018
M3 - Article
C2 - 37247462
AN - SCOPUS:85160314352
SN - 0924-977X
VL - 74
SP - 22
EP - 29
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
ER -